| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA910: Semaglutide for managing overweight and obesity in young people aged 12 to 17 (terminated) |
|
Medicine details |
|
| Medicine name | semaglutide (Wegovy®) |
| Formulation | 0.25mg, 0.5mg, 1mg. 1.7mg , 2.4 mg solution for injection |
| Reference number | 5245 |
| Indication | Weight management in adolescents with overweight or obesity aged 12 to 17 years old with a BMI equal to or above 95th percentile OR equal to or above 85th percentile with 1 or more weight related comorbidity (hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes) |
| Company | Novo Nordisk Ltd |
| BNF chapter | Endocrine system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 17/03/2023 |
| NICE guidance | TA910: Semaglutide for managing overweight and obesity in young people aged 12 to 17 (terminated) |